MedTrace Logo

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

NCT02251210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2014-09-29

No results posted yet for this study

Summary

To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic profile will be also obtained.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

BIIL 284 BS low dose

DRUG

BIIL 284 BS medium dose

DRUG

BIIL 284 BS high dose

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2002-11-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251210 on ClinicalTrials.gov